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Comprehensive studies support the notion that the peroxisome proliferator-activated receptors, (PPARs), PPARα,P P A R β/δ,a n d
PPARγ, regulate cell growth, morphogenesis, diﬀerentiation, and homeostasis. Agonists of each PPAR subtype exert their eﬀects
similarly or distinctly in diﬀerent tissues such as liver, muscle, fat, and vessels. It is noteworthy that PPARα or PPARγ agonists have
pharmacological eﬀects by modulating the activity of AMPK, which is a key cellular energy sensor. However, the role of AMPK in
the metabolic eﬀects of PPAR agonists has not been thoroughly focused. Moreover, AMPK activation by PPAR agonists seems to
be independent of the receptor activation. This intriguing action of PPAR agonists may account in part for the mechanistic basis
of the therapeutics in the treatment of metabolic disease. In this paper, the eﬀects of PPAR agonists on metabolic functions were
summarized with particular reference to their AMPK activity regulation.
1.Introduction
The peroxisome proliferator-activated receptors (PPARs) are
transcription factors that regulate diverse physiological and
pathological processes including cell growth, morphogen-
esis, diﬀerentiation, and homeostasis [1]. PPARs are well-
characterized receptors that belong to the nuclear hormone
receptor superfamily: they were originally isolated as nuclear
receptors that activate the proliferation of peroxisomes in the
cell in 1990s [1–3]. PPARs consist of three isoforms (i.e.,
PPARα,P P A R β/δ,a n dP P A R γ), whose tissue distributions
and functional roles are distinct [4]. After the discovery,
intensive studies on the biology of PPARs and their mod-
ulation by synthetic ligands have been conducted. Thus,
a myriad of research have identiﬁed natural or synthetic
PPAR ligands as pharmaceutical agents in the treatment
of metabolic disorders [1, 4]( Figure 1). Recently, it has
been recognized that PPAR agonists have physiological
eﬀects by modulating the activity of AMP-activated protein
kinase (AMPK), an important cellular energy sensor [5–
9]. However, this action seems to be independent of PPAR
receptor activation [5, 6, 9]. These ﬁndings suggest the
concept that PPAR agonists exert their eﬀects cooperatively
or synergistically with their cellular partners or associated
components. This paper focuses on the eﬀects of PPAR
agonists on metabolic functions with particular reference to
AMPK activity modulation.
2. Effects of PPAR Isoforms on
Metabolic Functions
Like conventional nuclear receptors, each PPAR contains
DNA-binding domain (DBD), ligand binding domain
(LBD), and ﬂexible hinge region. DBD has two zinc ﬁn-
ger motifs whereas LBD contains 13 alpha helices and a
small four-stranded beta sheet which composes a single
domain [10]. Many nuclear receptors bind with retinoid
X receptors (RXRs) as a modular heterodimeric partner,
which also belong to members of the nuclear receptor
superfamily; the RXRs possess a highly conserved central
DNA-binding domain and less conserved ligand-binding
domain [11]. Like other nuclear receptors, each PPAR forms
a heterodimer with RXRα as a permissive partner, and this
complex transactivates target genes for physiological activity
modulations. So, RXRα acts as a supporting factor for strong
DNA binding of PPAR. Ligand-mediated activation of the
nuclear receptor homodimers or heterodimers involves their2 PPAR Research
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Figure 1: The chemical structures of PPAR activators.
bindings to the DNA response element containing two core
recognitionsequences;thisconsensusDNAsequencepresent
in the promoter regions of target genes is called “peroxiso-
mal proliferator response element” (PPRE, 5 -AGGTCA-N-
AGGTCA-3 )[ 1]. Activation of PPARs with RXR contributes
to diverse physiological processes through initiation of gene
transcription, the protein products of which are required for
glucose/fat metabolism, inﬂammation, vascular physiology,
and muscle performance [1–4]. Hence, activated PPARs
regulate genes involved in the adaptation of cells or organs
to metabolic changes.
T h r e eP P A Ri s o f o r m sh a v ed i ﬀerent functional roles.
PPARα (NR1C1), which is mainly expressed in the liver,
heart, and kidney, shows high-catabolic rates of fatty
acids and peroxisome-mediated activities [4]. Long-chain
polyunsaturated fatty acids (especially, 20:5n-3 and 22:6n-3)
and leukotriene B4 are natural ligands for PPARα whereas
ﬁbrates (i.e., hypolipidemics) and WY14643 (pirinixic acid,
a nonsteroidal anti-inﬂammatory drug) are synthetic [12].
Activated PPARα promotes the expression of genes required
for fatty acid and lipoprotein metabolism in mitochondria,
peroxisomes, and endoplasmic reticulum [12]. Activation of
PPARα by agonists or fatty acids induces peroxisomal pro-
liferation, fatty acid oxidation, and the production of ketone
bodies; PPARα stimulates the inﬂux of fatty acids into the
mitochondria via carnitine palmitoyltransferase 1 (CPT1)
[12]. So, a deﬁciency of PPARα shows defects in hepatic fatty
acid uptake and oxidation in an animal model [13]. PPARα
activation increases plasma high-density lipoprotein (HDL)
levels, transporting HDL particles from peripheral tissues toPPAR Research 3
the liver with a decrease in plasma triglyceride (TG) level.
Therefore, PPARα agonists suppress dyslipidemia observed
in metabolic syndrome. Moreover, PPARα regulates energy
balanceinthebodybymodulatingenergyexpenditure.Since
uncoupling proteins (UCPs) contain PPREs in their gene
promoter regions, PPARα activators induce UCP1 in brown
adipose tissue, UCP2 in liver, and UCP3 in skeletal muscle
[14–16]. Recently, the role of PPARα in inﬂammation has
emerged, implying that this receptor negatively regulates
inﬂammatory responses [12].
Although PPARβ/δ is ubiquitously expressed in most
tissues, high level of PPARβ/δ (NR1C2) is observed in
skeletal muscle, suggesting that it is involved in energy
metabolism [17]. PPARβ/δ is engaged in membrane lipid
synthesis/turnover, and cell proliferation and diﬀerentiation
[17, 18]. Long-chain fatty acids and prostacyclin might
serve the endogenous ligands of PPARβ/δ. Erucic acid has a
higher aﬃnity for PPARβ/δ than other PPAR subtypes [19].
Activated PPARβ/δ promotes fatty acid oxidation in muscle
and is thought to be engaged in the adaptation of muscle
to fatty acid metabolism. Like PPARα,P P A R β/δ regulates a
series of genes involved in fatty acid catabolism and obesity
(e.g., UCP3, CPT1 and malonyl-CoA decarboxylase) [1].
Wang et al. have shown that VP16-PPARδ transgenic mice
with PPARδ activation in adipose tissue were resistant to
high-fat diet-induced and genetically predisposed obesity
and hyperlipidemia. By the same token, PPARδ knockout
(KO) mice showed reduced energy uncoupling and were
pronetoobesityunderhigh-fatdietfeeding[20].Inaddition,
PPARβ/δ is a sensor of very low-density lipoprotein (VLDL)
in macrophages, and may play a role in fat storage [21]. In
skeletal muscle, enforced expression of constitutively active
PPARβ/δ augmented oxidative muscle ﬁbers and enhances
running endurance [22, 23]. Consistently, PPARβ/δ over-
expression helps recover insulin resistance in obesity and
enhance insulin action and glucose tolerance [22, 23].
PPARγ (NR1C3) is expressed predominantly in the
adipose tissue and, to a lesser extent, in the liver. PPARγ
exists as three forms (γ1, γ2a n dγ3) by alternative splicing
[1]. PPARγ1i se x p r e s s e di nm o s tt i s s u e sw h e r e a sP P A R γ2
is present predominantly in adipose tissue. PPARγ3 shows
high expression in macrophages, white adipose tissue, and
large intestine. The results of gene KO study showed that the
homozygous KO of PPARγ impaired cardiac development,
resulting in intrauterine death [24]. In addition, PPARγ
heterozygous KO mice exhibited impaired glucose home-
ostasis and adipocyte function, but showed increased leptin
levels [25]. The PPARγ activators such as free fatty acids
(FFAs), eicosanoids and thiazolidinediones (TZD) induce
physiological changes through target gene induction [1,
4]. PPARγ activation in adipocytes suﬃciently improved
systemic insulin sensitization [26]. Adipose-speciﬁc PPARγ
activation by transgene expression and non-TZD PPARγ
agonist (AG035029) treatment prevented insulin resistance
equivalent to TZD treatment [26]. These results suggest that
fat-speciﬁc PPARγ agonists may be novel candidates for
diabetes. PPARγ is signiﬁcantly upregulated by the PPARγ
activators in the liver or under certain pathophysiological
states (e.g., obesity) although its basal expression is rather
low [27, 28]. Activation of PPARγ improves insulin sensitiv-
ity in liver and muscle, decreases the intracellular lipid level
in liver and muscle, and rescues insulin receptor signaling
in type 2 diabetes [29]. Also, PPARγ contributes to the
balance between lipid inﬂux and eﬄux in macrophages by
upregulating target genes (e.g., fatty acid transporters and
CD36) [28].
3. Regulatory Role of AMPK in
Metabolic Functions
AMPK plays a critical role in sensing and regulating energy
homeostasisincells[30].AMPKisaserine/threonineprotein
kinase which physiologically responds to the change in
the cellular AMP to ATP ratio. AMPK activation regulates
physiological and pathological responses in diverse tissues.
AMPK activation induces fatty acid oxidation in liver and
heart, inhibits hepatic lipogenesis and adipocyte diﬀeren-
tiation, and stimulates glucose uptake in muscle [30, 31].
AMPK is composed of 3 subunits (α, β,a n dγ): a catalytic
subunit (α1o rα2) and two regulatory subunits (β1o rβ2
and γ1, γ2o rγ3) [30]. AMPK activation is initiated with
phosphorylation of threonine-172 in the catalytic domain
of α subunit [31]. The γ subunit recognizes the AMP:ATP
ratio because this has the AMP binding domain. Elevated
level of AMP induces allosteric stimulation of AMPK. At
present, two upstream kinases of AMPK have been discov-
ered: LKB1 and Ca2+/calmodulin-dependent protein kinase
kinase (CaMKKβ)( Figure 2)[ 32, 33]. Transforming growth
factor β-activated kinase-1 might be another one [34]. Both
LKB1 and CaMKK directly phosphorylate thereonine-172
in AMPKα subunit in an AMP-independent fashion. LKB1,
also known as a tumor suppressor gene, is constitutively
active. The upstream kinases of LKB1 may comprise protein
kinase C (PKC)-ζ, protein kinase A, and ribosomal S6 kinase
(RSK) [35, 36]. However, several studies also suggested
that there may be LKB1-independent AMPK kinase based
on the ﬁndings that constitutive AMPK activity could be
detected even in LKB1-deﬁcient mice or cells (e.g., HeLa and
A549 cells) [37]. In addition, the result of CAMKK activity
regulation by calcium/calmodulin (Ca2+/CaM) indicated
that AMPK might be engaged in Ca2+ regulation in cells.
The important role of AMPK in glucose metabolism has
been investigated in cell or animal models. Insulin regulates
glucose utilization in major organs that maintain serum
glucose level, such as liver and muscle. When blood glucose
content is elevated, insulin secreted from the pancreatic beta
cellstimulatesthestorageofglucoseintheseorgans[38].The
binding of insulin to insulin receptor in the plasma mem-
brane transmits signals that induce diverse physiological
responses.Autophosphorylationofinsulinreceptortriggered
by insulin binding leads to activation of mammalian target
of rapamycin (mTOR)-p70 ribosomal S6 kinase-1 (S6K1)
via phosphatidylinositol 3-kinase (PI3K)/Akt pathway. This
mTOR/S6K ﬂow is linked to AMPK. Under the condition
of starvation, AMPK phosphorylates tuberous sclerosis 2
(TSC2),whichinhibitsmTOR/S6K1pathway[39]:phospho-
rylation of TSC2 by AMPK is critical in the process of mRNA4 PPAR Research
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Figure 2: The regulatory role of AMPK in metabolic functions.
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translation and cell size regulation during energy deﬁciency
(Figure 2). Thus, AMPK activation negatively regulates the
mTOR/S6K1 pathway.
Glycogen synthase kinase-3β (GSK3β), a Ser/Thr kinase,
isconstitutivelyactivatedinnormalstate.Phosphorylationat
the serine 9 residue inactivates GSK3β, which may promote
cell survival against ischemia/reperfusion injury by blocking
mitochondrial permeability transition pore opening [40].
It has been shown that resveratrol treatment inhibited
GSK3β activitydownstreamofAMP-activatedproteinkinase
(AMPK) activation, and which was responsible for mito-
chondrial protection [41]. AMPK induces upregulation of
the p53–p21 axis, which leads to G1 cell cycle arrest. It
has been reported that AICAR treatment caused cell cycle
arrest in various cell types (HepG2, mouse embryonic
ﬁbroblasts, and smooth muscle cells) [42]. AICAR promotes
phosphorylation oftumorsuppressorp53 (Ser15in human),
subsequently leading to p21 induction. In addition, the
possibility that increases in p21, p27, and p53 by AICAR
inhibit proliferation of several types of cancer cells has been
reported [43]. In summary, these results demonstrated that
AMPK plays a pivotal role in the regulation of cell cycle and
survival by aﬀecting several downstream signals.
AMPK activators mimic the actions of insulin in terms
of gluconeogenesis, repressing glucose production [44].
Therefore, the agents that activate AMPK are beneﬁcial
in the treatment of insulin resistance and diabetes [44].
Moreover, insulin induces glucose transporter 4 (GLUT4)
expression and its translocation, which facilitates glucose
uptake into cells [38]. Physiologically, exercise enables
GLUT4 to translocate into plasma membrane from vesicles
through AMPK. The role of AMPK in exercise-induced
glucose utilization is supported by the ﬁnding that treatment
with aminoimidazole carboxamide ribonucleotide (AICAR),
a direct AMPK activator, promoted glucose uptake, and
GLUT4 translocation in skeletal muscle [45]. Consequently,
4 weeks of AICAR treatment stimulated metabolic genes and
enhanced running endurance by 44% even in sedentary mice
[23].
AMPKisinvolvedinthemaintenanceoflipidandcholes-
terol homeostasis; it stimulates the β-oxidation of fatty acids
in mitochondria for lipid utilization [44]. AMPK inhibits the
activity of acetyl-CoA carboxylase (ACC) through phospho-
rylation (Figure 2). Under normal condition, ACC inhibits
CPT1 that transports fatty acids into mitochondria and
increases fatty acid oxidation. Inactivation of ACC by AMPK
helps promote fatty acid utilization, leading to fat burning
in liver and muscle. Liver X receptor α (LXRα) is the
lipid sensor that promotes fatty acid synthesis and leads
to hypertriglyceridemia. AMPK activation by metformin or
dithiolethiones represses LXRα activity via phosphorylating
threonine residue(s) of AMPK [46]. Moreover, AMPK
inhibits hepatic cholesterol synthesis by inhibiting HMG-
CoA reductase, a rate-controlling enzyme of the mevalonate
pathway. AMPK inhibits HMG-CoA reductase activity by
phosphorylation, which reduces cholesterol levels (Figure 2)
[47]. Similarly, AMPK activation attenuates TG synthesis
via the inhibition of LXRα activity in the liver, and thus
resultsinanantisteatoticeﬀect[46].Ofnote,S6K1activation
reverses this eﬀect of AMPK on LXRα-SREBP-1c pathway, as
mediated by the phosphorylation of LXRα at serine residue.
Vascularendotheliumisusuallyexposedtophysicalstress
(e.g., blood pressure or shear stress) even under normal
conditions.Consequently,damagedvasculaturecausesblood
coagulation and recruitment of immune cells. In particular,
free radical stress contributes to the pathologic processes of
cardiovascular diseases (e.g., atherosclerosis and coronary
heartdisease)[48,49].Apoptosisofendothelialcellsbyshear
stress or FFAs causes injury of endothelial cell monolayer,
provokes the migration of vascular smooth muscle cells
(VSMCs) into the intima, and facilitates plaque formation
[50]. Altered outer environment confers proliferation and
migration of VSMCs, which may be stimulated by the
cytokines and growth factors secreted from accumulated
immune cells in the plaque. Under these conditions, uncon-
trolled growth of VSMCs in conjunction with endothelial
cell death is critical for the development of atherosclero-
sis [50]. In addition, the production of reactive oxygen
species (H2O2 and O2
−) is ampliﬁed by the activation
of NAD(P)H oxidase, peroxidase, and cyclooxygenase in
these cells. AMPK may aﬀect vascular physiology. AMPK
activators including rosiglitazone and pioglitazone suppressPPAR Research 5
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high-glucose-induced hyperactivity of NAD(P)H oxidase in
human umbilical vein endothelial cells [51, 52]. In addition,
hypoxia-activated AMPK stimulates Akt that phosphorylates
and activates endothelial nitrogen oxide synthase (eNOS)
(Serine 1177) (Figure 2)[ 53, 54]. Thus, eNOS contributes to
the survival and function of endothelial cells through nitric
oxide (NO) production. Since AMPK responds to external
stressandregulatecellularhomeostasis,itsactivationenables
endothelial cells to survive against severe stress [53, 54].
4. The Link betweenPPAR Agonists and
AMPK-Dependent Metabolic Functions
4.1. Energy Metabolism. The metabolic disorder is a constel-
lation of impaired glucose/lipid metabolism, hypertension,
obesity, diabetes, and cardiovascular diseases [38]. Major
causes of the metabolic disorder include overweight, physical
inactivity, and high-carbohydrate diet that cause the distur-
bance of energy metabolism. A variety of metabolic diseases
are highly associated with insulin resistance, as deﬁned by
the desensitization of target cells to insulin. Insulin-resistant
diabetic patients are at high risk for developing hepatic
diseases. Also, peripheral insulin resistance is monitored in
mostpatientswithlivercirrhosis.Themajorcausesofinsulin
resistance are genetic (∼50%) and environment factors
including obesity (∼25%), and physical ﬁtness (∼25%) [55].
Since treatment of insulin resistance has beneﬁcial eﬀects on
diabetes, dyslipidemia, obesity, and atherosclerosis, AMPK
emerges as a therapeutic target for metabolic disorders [44].
Endurance exercise is the treatment recommended for
patients with metabolic disease. Intriguingly, PPARβ/δ
agonists serve exercise mimetics, as do AMPK activators
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Figure 4: The eﬀects of PPARα activators on AMPK-dependent
functions. eNOS: endothelial nitrogen oxide synthase; NF-κB:
nuclear factor-κB; PAI-1: plasminogen activator inhibitor-1; SHP,
small heterodimer partner.
[23]( Figure 3). Because PPARβ/δ shows high expres-
sion in skeletal muscle, treatment with PPARβ/δ ago-
nist (GW1516) reprogrammed gene expression involved
in oxidative metabolism in this tissue [23]. In addition,
GW1516 administration and exercise training exert syn-
ergistic eﬀects, as shown by the improvement of running
endurance in exercise-trained mice [23]. In this study,
GW1516 and AICAR synergistically increased transcription
of several oxidative genes in mice quadriceps (i.e., Scd1,
ATP citrate lyase, hormone sensitive lipase, muscle fatty
acid binding protein, Lpl, and Pdk4). AMPK directly
interacted with PPARβ/δ although it did not phosphorylate
PPARβ/δ; AMPK may form a transcriptional complex with
PPARβ/δ, which would strengthen the receptor activity
[23]. In addition, PPARβ/δ activation by GW1516 induced
SIRT1 gene transcription, which regulates body physiology
and metabolism [56]. These results suggest that PPARβ/δ
activates AMPK probably because SIRT1 contributes to
AMPK activation.
PPARα activators including fenoﬁbrate and WY14643
activate AMPK signaling pathway in a receptor-independent
manner (Figure 4). However, the mechanisms of these lig-
ands on AMPK activation diﬀer from each other. Fenoﬁbrate
induces the phosphorylation and activation of AMPK via
the induction of small heterodimer partner (SHP, an orphan
nuclear receptor) and its target genes [5]. On the other hand,
WY14643 treatment increased the expression of AMPKα1
and α2 mRNA, leading to increase in AMPKα subunit
phosphorylation and its enzymatic activity. However, the
mechanism for this activation remains elusive [6].
PPARγ agonists (i.e., TZDs) activate AMPK by phos-
phorylating AMPK independently of PPARγ activity [7–
9]( Figure 5). Troglitazone (10mg/kg, i.p.) increased the6 PPAR Research
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phosphorylations of AMPK and ACC rapidly (15min after
treatment) in skeletal muscle, liver, and adipose tissue of
intact rats [9]. Consistently, troglitazone caused two-fold
increases in 2-deoxy-d-glucose uptake in skeletal muscle
through AMPK activation. Clinically, pioglitazone also acti-
vatesAMPKsignalingandintensiﬁesmitochondrialfunction
and fat oxidation in the muscles of diabetic patients [29].
Collectively, TZDs stimulate adiponectin signals, activat-
ing AMPK, which regulates glucose metabolism and fat
catabolism [29, 57].
4.2. Metabolic Diseases. Insulin resistance is characterized
as the condition that higher level of insulin is required for
normal metabolic responses because normal level of insulin
fails to achieve these responses in peripheral organs. Hepatic
insulinresistancecausesdefectsinglycogensynthesis/storage
and disables glucose production/release [38, 58]. Insulin
resistance reduces glucose uptake in skeletal muscle, whereas
it hampers the normal insulin actions and enhances hydrol-
ysis of stored TG in fat tissue. Insulin resistance and the
consequent hyperinsulinemia develop into several metabolic
syndromessuchastype2diabetesmellitus,fattyliverdisease,
and atherosclerosis [38, 58] .S e v e r a lT Z D sh a v eb e e ns h o w n
to recover insulin resistance via AMPK activation [59–62].
Rosiglitazone promotes AMPK-mediated insulin secretion
via the phosphorylation of Kir6.2 subunit of the potassium
(ATP) channel in β-cells [62]. However, Prentiki and his col-
leagues reported that pioglitazone inhibits glucose-induced
insulin secretion although its antidiabetic eﬀect depended
on AMPK [60]. Therefore, the eﬀect of pioglitazone may
attribute to improve hyperinsulinemia and preserve β-cell
function. Like pioglitazone, troglitazone restrains insulin
hypersecretion at the high level of glucose and fatty acids,
leading to the rescue of β-cells from glucolipotoxicity [59].
Recently, BLX-1002, a novel TZD with no PPAR aﬃnity,
activates AMPK in β-cell. BLX-1002 raises cytoplasmic Ca2+
and enhances glucose-induced insulin secretion at high
glucose [61]. These results suggest that certain moiety(s)
of TZDs is (are) responsible for AMPK activation indepen-
dently of PPARγ activation. In the view of glucose uptake,
rosiglitazone remarkably enhanced AMPK-mediated glucose
uptake and glycogen synthesis in muscle and adipose tissues
[63]. Likewise, AICAR induced whole body glucose disposal
(27%) and glucose infusion rate (44%), which represents
improvement ofinsulinresistance.Incardiacmuscle,PPARα
and PPARγ activators stimulated glucose uptake via AMPK
[64].However,GW1506(aPPARβ/δ activator)hadnoeﬀects
on glucose uptake in rat L6 skeletal muscle cells [65].
Nonalcoholic fatty liver disease (NAFLD) is associ-
ated with metabolic syndrome and insulin resistance [58].
NAFLD represents the initiation step of hepatic metabolic
syndrome such as steatosis, steatohepatitis, and ﬁbrosis.
Insulin resistance induced mostly by obesity may cause
the development of hepatic steatosis; hyperinsulinemia
augments hepatic lipogenesis of TGs and fatty acids.
S e v e r a lA M P Ka c t i v a t o r ss u c ha sm e t f o r m i na n dT Z D s
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Table 1: The eﬀects of PPAR agonists on AMPK-dependent metabolic functions.
Isotypes PPAR agonists
AMPK-dependent functions
Liver Skeletal muscle Adipose tissue Vessel
PPARα Fenoﬁbrate Improved IR [12]
NAFLD↓ [5] —— eNOS↑ [69]
WY14,643 NAFLD↓ [5]— —eNOS↑ [70]
PPARβ/δ GW1516 —
Oxidative metabolism↑ [23]
Endurance activity↑ [23]
(in cooperation with AMPK)
— —
PPARγ
Rosiglitazone
Improved IR [66]
NAFLD↓ [66]
ASH↓ [57]
Glucose uptake↑ [63]
Glycogen synthesis↑ [63]
Glucose uptake↑ [63]
Glycogen synthesis↑ [63]
Oxidative stress↓ [52, 71]
Troglitazone Improved IR [59]
NAFLD↓ [72] Glucose uptake↑ [9]— —
Pioglitazone Improved IR [60]
NAFLD↓ [67]
Fat oxidation↑ [29]
Mitochondrial function↑ [29] — —
ASH: alcoholic steatohepatitis; IR: insulin resistance; NAFLD: nonalcoholic fatty liver disease.
intervention of hepatic steatosis [46, 66], suggesting that
signals downstream of the components activated by the
drugs with diﬀerent modes of action merge to the same
pathway. Treatment with either rosiglitazone or pioglitazone
attenuated hepatic steatosis and inﬂammation in patients
with nonalcoholic steatohepatitis (Figure 5)[ 66, 67]. In
addition, rosiglitazone ameliorated alcoholic fatty liver via
adiponectin/SIRT1/AMPK pathway in mice [57]. Nonethe-
less, TZDs must be used cautiously as adjuvant therapy for
nonalcoholic steatohepatitis treatment since they may pro-
voke congestive heart failure. In recent studies, the activation
of hypoxia inducible factor-1α (HIF1α)-PPARγ axis pro-
moted fatty acid uptake and glycerolipid biosynthesis genes,
leading to cardiac hypertrophy [68]. In C57BL/6 mice fed
a methionine-deﬁcient and choline-deﬁcient (MCD) diet,
fenoﬁbrate had an eﬀect to prevent the progressive ﬁbrosing
steatohepatitis. In this model, fenoﬁbrate induced AMPK-
mediated SHP gene expression, but reduced plasminogen
activator inhibitor-1 (PAI-1) mRNA and protein expression
[5]. Another PPARα agonist, WY14643 also ameliorated
steatohepatitis along with decrease in the gene expression
involved in fatty acid synthesis [5].
eNOS plays a role in the endothelium homeostasis
through NO production [50]. It has been shown that PPARα
agonistsincludingfenoﬁbrateandWY14643stimulateeNOS
activity and NO production in human umbilical vein
endothelial cells in association with AMPK activation [69,
70]. In mouse endothelial cells, AMPK activity modulation
by fenoﬁbrate contributes to inhibiting NF-κBa c t i v i t y ,
implying that the agent might attenuate atherosclerosis
development (Figure 4)[ 69]. Rosiglitazone also reduced
glucose-induced oxidative stress and increases eNOS enzyme
stimulation via AMPK activation [52, 71].
5. Concluding Remarks
PPAR agonists have diverse metabolic eﬀects both in vitro
and in vivo. The mechanisms of action include nutrients
(especially glucose and lipid) metabolism and maintenance
of energy homeostasis. Since AMPK is an important regula-
tor in energy metabolism, it may be a key downstream target
of PPARs, as indicated by the convergence of PPAR agonists’
actions on AMPK. Overall, the eﬀects of PPAR agonists
on AMPK-mediated metabolic functions may contribute to
the recovery of insulin sensitivity or treatment of metabolic
syndrome (Table 1).
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